Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences has demonstrated a positive outlook primarily due to the promising preliminary results of its lead product candidate, SENTI-202, showing a 42% complete response rate in relapsed/refractory acute myeloid leukemia (AML) patients. The company’s recent designation of Regenerative Medicine Advanced Therapy (RMAT) for SENTI-202 is expected to facilitate strategic engagement with the FDA, potentially expediting the pathway towards pivotal trials set for initiation in 2026. Furthermore, the significant reductions in leukemic stem cells while preserving normal hematopoietic stem and progenitor cells enhances the therapeutic potential of Senti's innovative CAR-NK cell therapies, reinforcing investor confidence in the company's future prospects.

Bears say

Senti Biosciences Inc. is facing potential downward revisions in its price target and risk-adjusted projections due to uncertainties surrounding its clinical-stage product candidates and overall market performance. Concerns about the viability of its therapies, particularly the SENTI-202 and SENTI-301A, may lead to adjustments in fundamental financial metrics that impact investor sentiment. Additionally, the repetitive indication of potential downward revisions highlights significant risks associated with the company's strategic direction and market positioning in the competitive biotechnology landscape.

SNTI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.